Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial

Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelanotide achieved statistically significant BMI ...

Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Phase 3 top-line results from its EMANATE trial evaluating setmelanotide in ...
BioSpace

Rhythm’s Imcivree Fails Late-Stage Weight Loss Trial in Rare Obesities

The Phase 3 EMANATE study is a basket trial looking at the efficacy of Rhythm Pharmaceuticals’ injectable obesity drug across four types of obesities driven by specific genetic mutations.
Pharmabiz

Rhythm Pharmaceuticals’ phase 3 EMANATE trial of setmelanotide fails to meet primary endpoints

Rhythm Pharmaceuticals’ phase 3 EMANATE trial of setmelanotide fails to meet primary endpoints: Boston Wednesday, March 18, 2026, 18:00 Hrs [IST] Rhythm Pharmaceuticals, Inc., a ...
TCTMD

EMANATE: Another NOAC Shown to Be Safe, Effective in the Setting of Cardioversion for A-fib

BARCELONA, Spain—Apixaban appears to be an effective and safe alternative to heparin plus a vitamin K antagonist (VKA) for patients with A-fib who are undergoing rapid cardioversion and require ...
Yahoo Finance

Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial

BOSTON, March 16, 2026 (GLOBE NEWSWIRE)-- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...

Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) is one of the most promising stocks under $100 to buy. On March 16, Rhythm Pharmaceuticals announced topline results from its global Phase 3 EMANATE trial, ...